<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053023</url>
  </required_header>
  <id_info>
    <org_study_id>206224</org_study_id>
    <nct_id>NCT04053023</nct_id>
  </id_info>
  <brief_title>Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects</brief_title>
  <official_title>An Open-label, Single Sequence Crossover, Drug Interaction Study to Investigate the Effect of Linerixibat (GSK2330672) on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking
      obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC],
      OCA, or both) the addition of linerixibat to OCA therapy may be considered following
      marketing approval. It is therefore important to characterize any potential effect of
      linerixibat on the pharmacokinetics of OCA in humans at clinically relevant dosages.
      Accordingly, a drug-drug interaction (DDI) study with linerixibat (potential perpetrator) and
      OCA (potential victim) will be conducted to inform both future clinical trials with
      linerixibat and the potential concomitant administration of these drugs in a clinical
      setting. This is a single-center, one part (with optional second part) open-label, single
      sequence crossover, drug interaction study to investigate the effect of linerixibat on plasma
      concentrations of OCA and OCA conjugates in healthy participants. Approximately 19
      participants will be enrolled in part A and further 19 participants in part B (if performed)
      in the study and will have a phone call follow-up till 7-14 days post-last linerixibat dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a non-randomized study. Eligible subjects will receive OCA and OCA+linerixibat in a fixed sequence.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- AUC(0-t) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- AUC(0-24) for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- Cmax for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- Ctrough for Total-OCA at Steady State: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Total-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Total-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Total-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Tauro-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Tauro-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Glyco-OCA: OCA Arm</measure>
    <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Glyco-OCA: OCA + Linerixibat Arm</measure>
    <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 52</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Number of Participants With Any AEs and SAEs</measure>
    <time_frame>Up to Day 52</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm</measure>
    <time_frame>Baseline (Day -1), and at Day 17</time_frame>
    <description>Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1), and at Day 38</time_frame>
    <description>Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm</measure>
    <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
    <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Pulse Rate: OCA Arm</measure>
    <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
    <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Respiratory Rate: OCA Arm</measure>
    <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
    <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Body Temperature: OCA Arm</measure>
    <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
    <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in SBP and DBP</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Respiratory Rate</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameter: Hemoglobin</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameter: Hematocrit</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Change From Baseline in Chemistry Parameter: Protein</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Blood samples were planned to be collected to analyze the chemistry parameter: protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 17</time_frame>
    <description>Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm</measure>
    <time_frame>Baseline (Day -1) and at Day 38</time_frame>
    <description>Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline</measure>
    <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
    <description>Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Cmax for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A- Tmax for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Cmax for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B- Tmax for Linerixibat: OCA + Linerixibat Arm</measure>
    <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
    <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Participants receiving obeticholic acid and linerixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2330672 (linerixibat)</intervention_name>
    <description>GSK2330672 is available as a tablet with unit dose strength of 45 mg.</description>
    <arm_group_label>Participants receiving obeticholic acid and linerixibat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic acid</intervention_name>
    <description>Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).</description>
    <arm_group_label>Participants receiving obeticholic acid and linerixibat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 80 years of age inclusive, at the time of signing the informed consent.

          -  Healthy, as determined by the investigator or medically qualified designee, based on a
             medical evaluation including medical history, physical examination, vital signs,
             laboratory tests, and ECG. A participant with a clinical abnormality or laboratory
             parameter (i.e., outside the reference range for the population being studied), which
             is not specifically listed in the eligibility criteria, may be included only if the
             investigator agrees in consultation with the GlaxoSmithKline (GSK) medical monitor and
             documents in the source documentation that the finding is unlikely to introduce
             additional risk factors and will not interfere with the study procedures or outcomes.

          -  Body weight &gt; 50 kilogram (kg) and body mass index (BMI) within the range 18.5 to 32
             kg per square meter (inclusive).

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and protocol.

          -  Male and female- A female participant is eligible to participate if she is not
             pregnant not breastfeeding, and at least one of the following conditions applies; not
             a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow
             contraceptive guidance during the treatment period and until at least 4 weeks after
             the last dose of study treatment. The investigator is responsible for review of
             medical history, menstrual history, and recent sexual activity to decrease the risk
             for inclusion of a woman with an early undetected pregnancy.

        Exclusion Criteria:

          -  Any active dermatologic disorder leading to or with the potential to cause pruritus or
             a recent history of unexplained clinically significant itching locally or generally
             within the prior 3 months

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones) and/or confirmed
             hepatocellular carcinoma or biliary cancer

          -  Participants with a history of cholecystectomy

          -  Current symptomatic cholelithiasis or inflammatory gall bladder disease

          -  Significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs;
             constituting a risk when taking the study intervention; or interfering with the
             interpretation of data

          -  Any clinically relevant abnormality identified at the screening medical assessment
             (physical examination/medical history) clinical laboratory tests, or 12-lead ECG

          -  Current episode, recent history (within 1 month of screening visit), or chronic
             history of clinically significant diarrhea

          -  Lymphoma, leukaemia, or any malignancy within the past 5 years except for basal cell
             or squamous epithelial carcinomas of the skin that have been resected with no evidence
             of metastatic disease for 3 years

          -  Any current medical condition (e.g. psychiatric disorder, senility, dementia, or other
             condition), clinical or laboratory abnormality, or examination finding that the
             investigator considers would put the participant at unacceptable risk, which may
             affect study compliance or prevent understanding of the aims or investigational
             procedures or possible consequences of the study

          -  Regular use of known drugs of abuse or history of drug abuse or dependence within 6
             months of the study

          -  Regular alcohol consumption within 6 months prior to the study defined as an average
             weekly intake of &gt;14 units for females and &gt;21 units for males. One unit is equivalent
             to 8 gram of alcohol: a glass (approximately [~] 240 milliliter [mL]) of beer, 1 small
             glass (~100 mL) of wine or 1 (~25 mL) measure of spirits

          -  History of or regular use of tobacco- or nicotine-containing products (confirmed by
             smokerlyzer test) in the 3 months prior to screening.

          -  Administration of any IBAT inhibitor (including linerixibat) or OCA in the 3 months
             prior to screening

          -  Past or intended use of over-the-counter or prescription medication (including
             vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a
             potential enzyme inhibitor) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless approved by the investigator in conjunction with GSK
             medical monitor.

          -  Current enrollment in a clinical trial, recent participation in a clinical trial and
             has received an investigational product within 30 days (or 5 half-lives of previous
             trial intervention, whichever is longer) before the first dose in the current study

          -  Exposure to more than 4 new chemical entities within 12 months before the first dose
             in the current study.

          -  Screening ALT or AST &gt;1.5 times the upper limit of normal (ULN)

          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin
             is fractionated and direct bilirubin &lt;35%)

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or positive Hepatitis C
             antibody test result at screening or within 3 months of the screening visit

          -  Positive serum pregnancy test at screening or positive urine pregnancy test at
             admission in WOCBP only

          -  Positive human immunodeficiency virus (HIV) antibody test

          -  QTc &gt;450 millisecond (msec) on ECG performed at screening.

          -  Positive pre-study drug/alcohol screen or positive drug/alcohol screen at any time
             during the study.

          -  Female participants unable or unwilling to comply with specific contraception
             restrictions.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56-day period.

          -  Unwillingness or inability to follow the procedures outlined in the protocol for the
             expected duration of study participation.

          -  Sensitivity to any of the study interventions, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or medical monitor, contraindicates
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <results_first_submitted>July 1, 2020</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2020</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>linerixibat (GSK2330672), obeticholic acid, drug interaction, primary biliary cholangitis, pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a data sharing agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04053023/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04053023/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, drug interaction study to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and OCA conjugates in healthy participants. The study was conducted at a single center in the United Kingdom.</recruitment_details>
      <pre_assignment_details>A total of 19 participants were enrolled in Part A. Part B was optional and since there was no clinical benefit seen in conducting Part B of this study, no participants were enrolled in Part B. The study was concluded following completion of Part A.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg</title>
          <description>In Period 1, participants received OCA 10 milligram (mg), tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19). In Period 2 participants were administered OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (study Day 20 to Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (study Day 20 to the morning of Day 38). There was no washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg</title>
          <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (study Day 1 to Day 19) in Period 1; followed by OCA 10 mg, tablets, orally, once daily (evening dose) for 18 days (study Day 20 to Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (study Day 20 to the morning of Day 38) in Period 2. There was no planned washout period between Period 1 and Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A: Period 1 (Day 1 to Day 19)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Period 2 (Day 20 to Day 38)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B: Period 1 (Day 1 to Day 19)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Period 2 (Day 20 to Day 38)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was concluded after complete analysis of Part A, there was no clinical benefit seen in conducting Part B of this study, no participants were enrolled in Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg</title>
          <description>In Period 1, participants received OCA 10 milligram (mg), tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19). In Period 2 participants were administered OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (study Day 20 to Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (study Day 20 to the morning of Day 38). There was no washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="B2">
          <title>Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg</title>
          <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (study Day 1 to Day 19) in Period 1; followed by OCA 10 mg, tablets, orally, once daily (evening dose) for 18 days (study Day 20 to Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (study Day 20 to the morning of Day 38) in Period 2. There was no planned washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="10.28"/>
                    <measurement group_id="B3" value="44.9" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White  White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2329.804" spread="43.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="782.528" spread="55.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2349.552" spread="43.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="787.007" spread="55.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.409" spread="41.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.403" spread="45.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.312" spread="53.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.680" spread="85.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- AUC(0-t) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- AUC(0-24) for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- Cmax for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- Ctrough for Total-OCA at Steady State: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Total-OCA at Steady State: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.3" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Total-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Total-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1116" spread="57.86113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1600" spread="57.50955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.5168" spread="66.65649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8972" spread="25.55139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8489" spread="27.08479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4411" spread="21.63264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8644" spread="21.08848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.337" spread="59.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.171" spread="53.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.701" spread="59.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours * nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.092" spread="53.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.820" spread="71.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.495" spread="61.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.609" spread="69.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.060" spread="83.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.3" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.5" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712.567" spread="61.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.486" spread="64.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744.365" spread="68.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.946" spread="64.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.347" spread="60.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.224" spread="61.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.014" spread="76.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.600" spread="124.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.3" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1741.969" spread="44.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.683" spread="58.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1757.140" spread="44.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654.629" spread="57.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.770" spread="39.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.633" spread="50.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.</description>
          <population>PK Parameters Population.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.043" spread="50.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.498" spread="85.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.3" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Total-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Total-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Total-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Total-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Tauro-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Tauro-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Tauro-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Tauro-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Glyco-OCA: OCA Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Glyco-OCA: OCA Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Glyco-OCA: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
        <time_frame>Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Glyco-OCA: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
        <time_frame>Up to Day 52</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.</description>
          <population>All Participants Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Number of Participants With Any AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.</description>
        <time_frame>Up to Day 52</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Number of Participants With Any AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm</title>
        <description>Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm</title>
          <description>Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Millisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="14.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="13.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm</title>
        <description>Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm</title>
          <description>Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Millisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF</title>
        <description>Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF</title>
          <description>Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm</title>
        <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm</title>
          <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm</title>
        <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm</title>
          <description>SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Pulse Rate: OCA Arm</title>
        <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Pulse Rate: OCA Arm</title>
          <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm</title>
        <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm</title>
          <description>Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Respiratory Rate: OCA Arm</title>
        <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Respiratory Rate: OCA Arm</title>
          <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm</title>
        <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm</title>
          <description>Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Body Temperature: OCA Arm</title>
        <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1), Days 1 and 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Body Temperature: OCA Arm</title>
          <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm</title>
        <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm</title>
          <description>Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in SBP and DBP</title>
        <description>SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in SBP and DBP</title>
          <description>SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Respiratory Rate</title>
        <description>Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Respiratory Rate</title>
          <description>Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Body Temperature</title>
        <description>Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Body Temperature</title>
          <description>Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.0549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.4444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.8205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="22.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.7760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.0801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.169" spread="0.3534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.0932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.278" spread="1.2073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.524" spread="1.1981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0003" spread="0.01614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0054" spread="0.01857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="1.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="1.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm</title>
        <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm</title>
          <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.1919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0004" spread="0.01165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.2340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0074" spread="0.01650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameter: Hematocrit</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameter: Hematocrit</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes</title>
        <description>Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes</title>
          <description>Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" spread="0.0891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0395" spread="0.32717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.0506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, n=16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1507" spread="0.24902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" spread="0.88192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin, n=16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3126" spread="0.79317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, n=17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="38.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, n=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, n=16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea</title>
        <description>Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea</title>
          <description>Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</title>
        <description>Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</title>
          <description>Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST</title>
        <description>Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST</title>
          <description>Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Change From Baseline in Chemistry Parameter: Protein</title>
        <description>Blood samples were planned to be collected to analyze the chemistry parameter: protein.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Change From Baseline in Chemistry Parameter: Protein</title>
          <description>Blood samples were planned to be collected to analyze the chemistry parameter: protein.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm</title>
        <description>Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
        <time_frame>Baseline (Day -1) and at Day 17</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm</title>
          <description>Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cellular casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm</title>
        <description>Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
        <time_frame>Baseline (Day -1) and at Day 38</time_frame>
        <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm</title>
          <description>Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.</description>
          <population>All Participants Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cellular casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline</title>
        <description>Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.</description>
        <time_frame>Baseline (Day -1), and up to Day 38</time_frame>
        <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5 mg or 10 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 19 days (from study Day 1 to Day 19) in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline</title>
          <description>Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.</description>
          <population>All Participants Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
          <units>Hours*picogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 20, n=16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.609" spread="153.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33, n=19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903.881" spread="142.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
          <units>Hours*picogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 20, n=13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.580" spread="121.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33, n=17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1071.982" spread="144.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Cmax for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Cmax for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
          <units>Picogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 20, n=17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.927" spread="173.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33, n=19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.624" spread="123.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A- Tmax for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
            <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A- Tmax for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.</description>
          <population>PK Parameters Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 20, n=17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="0.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33, n=19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="0.5" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Cmax for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Cmax for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B- Tmax for Linerixibat: OCA + Linerixibat Arm</title>
        <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
        <time_frame>Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose</time_frame>
        <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: OCA 5mg or 10mg + Linerixibat 180 mg</title>
            <description>In Part B, participants were planned to receive OCA 5 mg or 10 mg, tablets, orally, once daily (evening dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 180 mg, tablets, orally, once daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B- Tmax for Linerixibat: OCA + Linerixibat Arm</title>
          <description>Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.</description>
          <population>PK Parameters Population. Data was not collected as no participants were enrolled in Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected up to Day 52 in Part A</time_frame>
      <desc>All Participants Population consisted of all participants who took at least 1 dose of study intervention. Data is presented for Part A only as data was not collected for Part B since there was no clinical benefit seen in conducting Part B of this study. The study was concluded following completion of Part A.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: OCA 10 mg</title>
          <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 19 days (study Day 1 to Day 19) in Period 1.</description>
        </group>
        <group group_id="E2">
          <title>Part A: OCA 10 mg + Linerixibat 90 mg</title>
          <description>In Part A, participants received OCA 10 mg, tablets, orally, once daily (afternoon dose) for 18 days (from study Day 20 to the Day 37) along with linerixibat 90 mg, tablets, orally, twice daily for 18.5 days (from study Day 20 to the morning of Day 38) in Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

